NEW YORK – Flow cytometry startup BennuBio has closed on $5 million of a $7 million Series B financing round, which it plans to use to expand commercial efforts, accelerate development of new features for its initial product, and develop additional complementary products.
The funding round was led by new investor Co-Win Ventures, with additional investment by existing investors Tramway Partners, Cottonwood Technology Fund, and Sun Mountain Capital. Xin Huang, managing partner at Co-Win Ventures, will also join BennuBio's board of directors.